Thryv Therapeutics Licenses a New Class of SGK1 Inhibitors from Spain's CSIC and Universidad Autónoma de Madrid, Extending Its Platform into Neurodegenerative Disease

Summary

Thryv Therapeutics has secured an exclusive worldwide license for a structurally distinct SGK1 inhibitor scaffold from CSIC and Universidad Autónoma de Madrid. The licensed asset targets neurodegenerative and cardiovascular indications including Parkinson's disease and Alzheimer's disease.